Last reviewed · How we verify
INO-9012
At a glance
| Generic name | INO-9012 |
|---|---|
| Also known as | IL-12 DNA adjuvant, IL-12 |
| Sponsor | Steven Deeks |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site reaction
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (PHASE1, PHASE2)
- INO 5401 Vaccination in BRCA1/2 Mutation Carriers (PHASE1)
- Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (PHASE1)
- INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (PHASE1, PHASE2)
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC (PHASE1, PHASE2)
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (PHASE2)
- Therapeutic Vaccination in Treated HIV Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INO-9012 CI brief — competitive landscape report
- INO-9012 updates RSS · CI watch RSS
- Steven Deeks portfolio CI